SCHEMBL3665719

SCHEMBL3665719

CC1(C)OB(c2ccc(NC(=O)Nc3ccccc3)nc2)OC1(C)C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 5/20 0.62
KDR P35968 5/20 0.62
RAB9A P51151 5/20 0.52
NPC1 O15118 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.50
ADORA3 P0DMS8 1/20 0.50
PIM1 P11309 1/20 0.50
ADORA2A P29274 1/20 0.50
ADORA2B P29275 1/20 0.50
ADORA1 P30542 1/20 0.50
FLT3 P36888 1/20 0.50
PIM3 Q86V86 1/20 0.50
AURKB Q96GD4 1/20 0.50
DGAT1 O75907 5/20 0.46
TSHR P16473 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
GBA1 P04062 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3697633 0.86 RAB9A (0.64) PDGFRBKDRRAB9ANPC1SMN1; SMN2
SCHEMBL423204 0.85 PDGFRB (0.61) PDGFRBKDRRAB9ANPC1SMN1; SMN2
SCHEMBL14872842 0.84 DGAT1 (0.48) PDGFRBKDRDGAT1L3MBTL1
SCHEMBL3411384 0.84 DGAT1 (0.50) PDGFRBKDRRAB9ADGAT1
SCHEMBL24233062 0.84 NPC1 (0.59) PDGFRBKDRRAB9ANPC1SMN1; SMN2
SCHEMBL29373917 0.84 NPC1 (0.59) PDGFRBKDRRAB9ANPC1SMN1; SMN2
SCHEMBL59458 0.83 KMT2A (0.66) PDGFRBKDRRAB9ANPC1L3MBTL1
SCHEMBL12314957 0.83 HCAR3 (0.56) PDGFRBKDRRAB9ANPC1SMN1; SMN2
SCHEMBL3666256 0.83 SMN1; SMN2 (0.59) PDGFRBKDRRAB9ANPC1SMN1; SMN2
SCHEMBL1181203 0.81 PTK2 (0.51) PDGFRBKDRRAB9ADGAT1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8901152-B2 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme ABBVIE INC. (US) 2014-12-02 US disclosed
US-20120277223-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBVIE INC. 2012-11-01 US disclosed
US-8242139-B2 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme ABBOTT LABORATORIES (US) 2012-08-14 US disclosed
WO-2012087938-A1 QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2012-06-28 WO disclosed
EP-2452937-A1 Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme Abbott Laboratories (US) 2012-05-16 EP disclosed
EP-2142521-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME Abbott Laboratories (US) 2010-01-13 EP disclosed
US-20080312282-A1 Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme ABBOTT LABORATORIES (US) 2008-12-18 US disclosed
WO-2008134693-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312282-A1 Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme DGAT1, DGAT2, LCAT PDGFRB 3184/4885KDR 4482/4885RAB9A 1874/4885
US-20120277223-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME DGAT1, DGAT2, LCAT PDGFRB 3184/4885KDR 4482/4885RAB9A 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.